Show Summary Details
Page of

Buprenorphine* 

Buprenorphine*
Chapter:
Buprenorphine*
Author(s):

Mellar P. Davis

DOI:
10.1093/med/9780199236640.003.0012
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 30 March 2020

Chapter 12 discusses Buprenorphine, a methylvinyl ketone adduct of theobaine which was developed in the 1960s. It is classified as a partial mu agonist, but some refer to it as an agonist–antagonist. Buprenorphine binds to mu, kappa1, kappa3, and orphan-related ligand-1 (ORL-1) receptors. Interest in buprenorphine has increased because of its relative safety in addiction maintenance therapy, its ‘ceiling’ effect on respiratory depression, and unique anti-hyperalgesic activity, which differs from that of potent mu opioids such as fentanyl or methadone. Buprenorphine has been used extensively to manage cancer pain. The development of a transdermal matrix patch has increased its use for cancer and non-cancer pain in countries where the patch is available.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.